Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Locke FL, et al. Among authors: goy a. Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2. Lancet Oncol. 2019. PMID: 30518502 Free PMC article. Clinical Trial.
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Dang NH, et al. Among authors: goy a. Oncol Rep. 2003 Sep-Oct;10(5):1513-8. Oncol Rep. 2003. PMID: 12883733 Clinical Trial.
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Dang NH, et al. Among authors: goy a. J Clin Oncol. 2004 Oct 15;22(20):4095-102. doi: 10.1200/JCO.2004.03.071. Epub 2004 Sep 7. J Clin Oncol. 2004. PMID: 15353540 Clinical Trial.
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Goy A, et al. J Clin Oncol. 2005 Feb 1;23(4):667-75. doi: 10.1200/JCO.2005.03.108. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613697 Clinical Trial.
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. Romaguera JE, et al. Among authors: goy a. J Clin Oncol. 2005 Oct 1;23(28):7013-23. doi: 10.1200/JCO.2005.01.1825. Epub 2005 Sep 6. J Clin Oncol. 2005. PMID: 16145068 Clinical Trial.
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Dang NH, et al. Among authors: goy a. Br J Haematol. 2007 Aug;138(4):502-5. doi: 10.1111/j.1365-2141.2007.06684.x. Epub 2007 Jun 29. Br J Haematol. 2007. PMID: 17608763 Free article. Clinical Trial.
245 results